Table 6. Costs and quality of life detriments associated with rotavirus vaccination at a coverage of 94.7% during 2015–2019 and without vaccination.
| Cost category | Mean (0.20; 0.80) cost without vaccination (€ 1000) |
Mean (0.20; 0.80) cost with vaccination (€ 1000) |
Avoided Mean (%) (€ 1000) |
|
|---|---|---|---|---|
| Healthcare costs | GP consultations | 822 (456;1 091) | 256 (142; 340) | 566 (69%) |
| EOC consultations | 508 (250; 685) | 158 (67; 236) | 350 (69%) | |
| Inpatient visits | 16 288 (13 171; 18 967) | 4 538 (3 645; 5 302) | 11 750 (72%) | |
| Outpatient visits | 673 (621; 719) | 187 (171; 202) | 486 (72%) | |
| Productivity losses | Home care | 47 805 (34 683; 57 205) | 19 696 (14 256; 23 597) | 28 109 (59%) |
| Primary care | 16 793 (14 614; 18 704) | 6 091 (5 275; 6 798) | 10 702 (64%) | |
| Hospital care | 4 868 (3 348; 5 920) | 1 577 (1 078; 1 924) | 3 291 (68%) | |
| QALY detriments | Morbidity | 212 (182; 243) | 50 (32; 69) | 137 (65%) |
| Mortality | 57 (0; 116) | 15 (0; 22) | 43 (75%) | |
| Vaccination costs | Rotarix® | 0 (0; 0) | 21 640 (20 996; 22 200) | NA |
| RotaTeq® | 0 (0; 0) | 22 580 (21 802; 23 248) | NA | |